Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Braeu, N., D. Wyles, S. Kottilil, E. Darr, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase.” In Journal of the International Aids Society, Vol. 19. JOHN WILEY & SONS LTD, 2016.

Scholars@Duke

Patel, Keyur, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, Per Lindell, and David Suhy. “258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV).” In Molecular Therapy, 24:S102–S102. Elsevier BV, 2016. https://doi.org/10.1016/s1525-0016(16)33067-2.

Full Text

Bhagani, S., C. Cooper, S. Naggie, M. Saag, J. Yang, L. Stamm, M. Natha, et al. “Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir.” Hiv Medicine 17 (April 1, 2016): 38–38.

Scholars@Duke

Alam, Imtiaz, Kimberley Brown, Cynthia Donovan, Jamie Forlenza, Kris Lauwers, Mitchell A. Mah’moud, Richard A. Manch, et al. “Su1426 Effectiveness of Simeprevir-Containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: The SONET Study.” In Gastroenterology, 150:S1096–97. Elsevier BV, 2016. https://doi.org/10.1016/s0016-5085(16)33703-9.

Full Text

Ruane, Peter J., Gamal Shiha, Armand Abergel, Tarik Asselah, Anita Kohli, Shyam Kottilil, Susanna Naggie, et al. “756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection.” In Gastroenterology, 150:S1047–48. Elsevier BV, 2016. https://doi.org/10.1016/s0016-5085(16)33541-7.

Full Text

Esmat, G. E., G. Shiha, A. Abergel, T. Asselah, A. Kohli, S. Kottilil, P. J. Ruane, et al. “INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION.” In Journal of Hepatology, 64:S769–S769. ELSEVIER SCIENCE BV, 2016.

Scholars@Duke

Alam, I., K. Brown, C. Donovan, J. Forlenza, K. Lauwers, M. A. Mah’moud, R. Manch, et al. “Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study.” In Journal of Hepatology, 64:S773–S773. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)01507-5.

Full Text

Wyles, D., N. Brau, S. Kottilil, E. Daar, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study.” In Journal of Hepatology, 64:S188–89. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)00129-x.

Full Text

Suhy, David, Keyur Patel, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, and Per Lindell. “Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).” Hepatology 62, no. 6 (December 1, 2015): 1386A-1386A.

Scholars@Duke

Muir, Andrew J., and Susanna Naggie. “Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?.” Clin Gastroenterol Hepatol 13, no. 12 (November 2015): 2166–72. https://doi.org/10.1016/j.cgh.2015.07.015.

PMID
26192145
Full Text

Pages